Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Recent Business Highlights
Provided By GlobeNewswire
Last update: Mar 21, 2024
Lead program, TIDAL-01, advancing in Phase 1 trials with initial clinical data expected in mid-2024
Promising preclinical data highlighting Turnstone’s novel Selected TIL programs for solid tumors presented at SITC 2023
Read more at globenewswire.com0.3345
-0.02 (-6.22%)
Find more stocks in the Stock Screener
TSBX Latest News and Analysis
10 days ago - ChartmillWhich stocks have an unusual volume on Wednesday?Join us as we delve into today's session and uncover the stocks that are standing out with unusual volume.
